ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 1761 • ACR Convergence 2024

    Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry

    Sabrina George1, Hannah C Ainsworth2, Kaiyu Jiang3, Gilad Barshad4, Adam He4, Edward Rice4, Carl D Langerfeld2, Charles G Danko4 and James N Jarvis3, 1University at Buffalo Jacobs School of Medicine, Buffalo, NY, 2Wake Forest University, Winston-Salem, NC, 3University of Washington School of Medicine, Seattle, WA, 4Cornell University Baker School of Veterinary Medicine, Ithaca, NY

    Background/Purpose: - Numerous juvenile idiopathic arthritis (JIA) risk loci have been identified, overwhelmingly from cohorts of children of European ancestry (EA). The extent to which…
  • Abstract Number: 2653 • ACR Convergence 2024

    Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis

    Elaine Yung1, Xiaoxuan Liu2, Bin Huang3, Michael Wagner1, Minal Aundhia2, Chen Chen4 and hermine brunner5, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 4Cincinnati Children's Hospital Medical Center, Cin, OH, 5Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life.  A common goal of treatment is to…
  • Abstract Number: 0353 • ACR Convergence 2023

    Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods

    Patricia Hoffman1, Lauren Parlett2, Daniel Beachler2, Daniel Reiff3, Sarah McGuire1, Sonia Pothraj1, Lakshmi Moorthy1, Cynthia Salvant4, Dawn Koffman5, Sanika Rege5, Cecilia Huang5, Matthew Iozzio5, Kevin Schott2, Kevin Haynes6, Amy Davidow7, Stephen Crystal8, Tobias Gerhard5, Brian Strom9, Carlos Rose10 and Daniel Horton4, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Carelon, Wilmington, DE, 3University of Alabama at Birmingham, Birmingham, AL, 4Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 5Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, 6Janssen Pharmaceuticals, Raritan, NJ, 7New York University, New York, NY, 8Rutgers University, New Brunswick, NJ, 9Rutgers, State University of New Jersey, New Brunswick, NJ, 10Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Administrative claims databases represent important settings for studying large populations with juvenile idiopathic arthritis (JIA), but prior efforts to validate diagnostic algorithms for JIA…
  • Abstract Number: 0374 • ACR Convergence 2023

    Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry

    Bashayer Alnuaimi1, Michelle Batthish2, Roberta A Berard3, Gilles Boire4, Sarah Campillo1, Amieleena Chhabra5, Julie Couture6, Paul Dancey7, Brian Feldman8, Tommy Gerschman9, Julie Herrington10, Kristin Houghton11, Adam Huber12, Claire LeBlanc1, Lillian Lim13, Jean-Philippe Proulx-Gauthier6, Heinrike Schmeling14, Rosie Scuccimarri1, Lori Tucker15, Jaime Guzman15, Gaëlle Chédeville1 and For The CAPRI Registry Investigators16, 1McGill University Health Center, Montreal, QC, Canada, 2McMaster Children's Hospital, Hamilton, ON, Canada, 3Children's Hospital - London Health Sciences Centre, London, ON, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5British Columbia Hospital, Vancouver, BC, Canada, 6CHU de Quebec- Universite Laval, Quebec City, QC, Canada, 7Memorial University of Newfoundland, St. John's, NL, Canada, 8The Hospital for Sick Children, Toronto, ON, Canada, 9British Columbia Children's Hospital, Burnaby, BC, Canada, 10McMaster University, Hamilton, ON, Canada, 11British Columbia University, Vancouver, BC, Canada, 12IWK Health Centre, Halifax, NS, Canada, 13University of Alberta, Edmonton, AB, Canada, 14University of Calgary, Calgary, AB, Canada, 15British Columbia Children's Hospital, Vancouver, BC, Canada, 16CAPRI, Montreal, QC, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
  • Abstract Number: 1240 • ACR Convergence 2023

    Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash

    Ilaria Maccora1, Patricia Vega-Fernandez2, Kimberly Risma3 and Grant Schulert4, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2Division of Rheumatology, Cincinnati Children's Hospital, Medical Centre, Cincinnati, OH, 3Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…
  • Abstract Number: 2506 • ACR Convergence 2023

    Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation

    Meena Afroze Shanta1, Anil Singh2, Paul Panipinto3 and Salahuddin Ahmed2, 1College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, 2Washington State university, Spokane, WA, 3Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA

    Background/Purpose: Chronic synovitis is a debilitating manifestation of juvenile idiopathic arthritis (JIA). Synovial fibroblast is a major preparator of inflammatory arthritis and has not been…
  • Abstract Number: 0354 • ACR Convergence 2023

    Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks

    Nicolino Ruperto1, Daniel J Lovell2, Sarah Ringold3, Xie L. Xu4, Jocelyn H. Leu3, Edwin Lam3, Yuhua Wang3, Alberto Martini5 and Hermine Brunner6, 1IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, 2UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, 3Janssen Research & Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC, San Diego, CA, 5Universita degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, 6Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH

    Background/Purpose: The phase 3, Intravenous Golimumab in Pediatric Participants with Active Polyarticular-Course JIA Despite MTX (GO-VIVA) study demonstrated that golimumab (GLM) 80 mg/m2 at Week…
  • Abstract Number: 0375 • ACR Convergence 2023

    Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR) Can Be Improved by Bi-lateral Alternating Stimulation Tactile (BLAST) Armbands

    Lea Höfel, Bruno Eppler, Johannes-Peter Haas and Boris Hugle, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany

    Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of children with juvenile idiopathic arthritis (JIA), and intolerance to the drug frequently leads to discontinuation…
  • Abstract Number: 1259 • ACR Convergence 2023

    Voices Unheard: Unmasking the Hidden Challenges of Youth with Rheumatic Diseases

    Natasha Trehan1, Laurie Proulx2 and Isabel Dukes3, 1University of Ottawa, Take a Pain Check Foundation, Toronto, ON, Canada, 2Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, 3CAPA & TAPC, Freelance, Ottawa, ON, Canada

    Background/Purpose: Rheumatic disease doesn't merely present physical challenges—it also significantly impacts various psychological and social aspects of one's life, often disrupting academic progress, straining friendships,…
  • Abstract Number: 2569 • ACR Convergence 2023

    Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease

    Sara Bindoli1, Arianna De Matteis2, STEPHANE MITROVIC3, Bruno Fautrel4, Loreto Carmona5, Fabrizio De Benedetti6 and On Behalf Of The Eular/PreS QoC011 Task Force Member7, 1Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, 2IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 3Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, 4Sorbonne Université APHP, Paris, France, 5Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 6Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, 7EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France

    Background/Purpose: To investigate the efficacy and safety of therapies currently in use and under evaluation for systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's disease…
  • Abstract Number: 0355 • ACR Convergence 2023

    Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis

    Ana Isabel Rebollo Gimenez1, Luca Carlini2, Paivi Miettunen3, Ekaterina Alexeeva4, Charlotte Myrup5, Rebecca Nicolai6, Maria Trachana7, Valda Stenevicha8, Constantin Ailioaie9, Elena Tsitsami10, Alexis-Virgil Cochino11, Chiara Pallotti12, Silvia Scala12, Angela Pistorio13, Sebastiaan Vastert14, Joost Swart15 and Nicolino Ruperto16, 1IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 2IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, 3University of Calgary and Alberta Children’s Hospital, Calgary, AB, Canada, 4Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 5Pediatric rheumatology unit 4272, Rigshospitalet, Copenhagen, Denmark, 6Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 7First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Thessaloniki University School of Medicine, Thessaloniki, Greece, 8Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, 9Pediatric Rheumatology , Alexandru Ioan Cuza University of Iasi, Iasi, Romania, 10Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, 11First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Childrens Hospital, Athens, Greece, 12Pediatric and Rheumatology Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 13Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 14University Medical Center Utrecht, Utrecht, Netherlands, 15Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, 16IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy

    Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…
  • Abstract Number: 0376 • ACR Convergence 2023

    Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis

    Daniel clemente Garulo1, Alina Lucica Boteanu2, Laura Trives Folguera3, Antía Asunción García Fernández2, lydia Abasolo4, Leticia Leon5, Juan Carlos López Robledillo6 and Juan carlos Nieto-Gonzalez7, 1Pediatric Rheumatology Unit, Hospital Niño Jesús, Madrid, Spain, 2Hospital Universitario Ramon y Cajal, Madrid, Spain, 3Hospital Universitario Infanta Sofía, Madrid, Spain, 4Hospital Clínico San Carlos, Madrid, Spain, 5Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, 6Hospital Universitario Niño Jesus, Madrid, Spain, 7Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: New therapies have improved the therapeutic management of juvenile idiopathic arthritis (JIA), allowing disease control in cases that are refractory or intolerant to methotrexate.…
  • Abstract Number: 1655 • ACR Convergence 2023

    Usability Testing of JIActiv, an Instagram-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis

    Zeinab Ahmadian Sangkar1, Fatou Bagayogo2, Karina Cristea2, Ciaran Duffy3, Jennifer Stinson4, Karine Toupin April3, Michele Gibbon5, Marianne Boulet1, Élodie Bolduc1, Aymane Alilou6, Sara Ahmed7, Claudine Auger1, Laurie Proulx8, Alexandra Sirois9 and Sabrina Cavallo10, 1University of Montreal, Montreal, QC, Canada, 2CRIR, Montreal, QC, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Children's Hospital of Eastern Ontario RI, Ottawa, ON, Canada, 6Unviersity of Montreal, Montreal, QC, Canada, 7McGill University, Montreal, QC, Canada, 8Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, 9CARRA, Outremont, QC, Canada, 10University of Montreal, Montréal, QC, Canada

    Background/Purpose: This study evaluated the usability (user performance and satisfaction) of an Instagram-based educational and interactive program promoting physical activity among young people living with…
  • Abstract Number: PP14 • ACR Convergence 2023

    Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease

    Natasha Trehan1 and Naomi Abrahams2, 1University of Ottawa, Take a Pain Check Foundation, Toronto, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada

    Background/Purpose: Naomi was diagnosed with Juvenile Idiopathic Arthritis (JIA) at the age of 18, after enduring 3 years of misdiagnoses. Similarly, Natasha received a diagnosis…
  • Abstract Number: 0357 • ACR Convergence 2023

    Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting

    Pamela F. Weiss1, Nicolino Ruperto2, Erhard Quebe-Fehling3, Alexis Shew4, Luminita Pricop5, Christelle Pieterse3 and Hermine Brunner6, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, St. Louis, MO, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH

    Background/Purpose: The juvenile spondyloarthritis disease activity index (JSpADA) is a disease activity assessment tool developed for children with juvenile psoriatic arthritis (JPsA) and enthesitis related…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology